You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Product overview

Incruse Ellipta is used to treat chronic obstructive pulmonary disease (COPD) in adults. Incruse Ellipta exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic cholinergic receptors on airway smooth muscle, making it easier for air to get in and out of the lungs. When used regularly, it can help control breathing difficulties and improve health-related quality of life. [1]

Incruse, Relvar and Ellipta are registered trademarks of the GlaxoSmithKline group of companies